	US 12,358,980 B2
	Compositions and methods for anti-PACAP antibodies
Anthony Gerard Doyle, Drummoyne (AU); Adam Clarke, Riverstone (AU); Danyal Butt, St. Leonards (AU); David Laine, Gladesville (AU); Hugh MacRae, Newtown (AU); Jenny Vo, Melrose Park (AU); Julia Rozenfeld, Gordon (AU); and Sachin Surade, Waitara (AU)
Assigned to CEPHALON LLC, West Chester, PA (US)
Filed by Cephalon, LLC, West Chester, PA (US)
Filed on Jul. 28, 2022, as Appl. No. 17/815,749.
Claims priority of provisional application 63/226,875, filed on Jul. 29, 2021.
Prior Publication US 2023/0212281 A1, Jul. 6, 2023
Int. Cl. C07K 16/26 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/26 (2013.01) [A61K 39/00 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. An anti-pituitary adenylate-cyclase-activating polypeptide (PACAP) antibody, wherein said antibody comprises heavy chain variable region (VH)-CDR1, VH-CDR2, and VH-CDR3 sequences set forth in SEQ ID NOs: 9, 2, and 3, respectively; and light chain variable region (VL)-CDR1, VL-CDR2, and VL-CDR3 sequence set forth in SEQ ID NOs: 10, 5, and 6, respectively.